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ABSTRACT Amyloid ﬁbrillation has been intensively studied because of its association with various neurological disorders.
While extensive time-dependent ﬁbrillation experimental data are available and appear similar, fewmechanisticmodels have been
developed to unify those results. The aim of this work was to interpret these experimental results via a rigorous mathematical model
that incorporates the physical chemistry of nucleation and ﬁbril growth dynamics. A three-stage mechanism consisting of protein
misfolding, nucleation, and ﬁbril elongation is proposed and supported by the features of homogeneous ﬁbrillation responses.
Estimated by nonlinear least-squares algorithms, the rate constants for nucleation were;10,000,000 times smaller than those for
ﬁbril growth. These results, coupled with the positive feedback characteristics of the elongation process, account for the typical
sigmoidal behavior during ﬁbrillation. In addition, experiments with different proteins, various initial concentrations, seeding versus
nonseeding, and several agitation rateswere analyzedwith respect to ﬁbrillation using our newmodel. Thewide applicability of the
model conﬁrms that ﬁbrillation kinetics may be fairly similar among amyloid proteins and for different environmental factors.
Recommendations on further experiments and on the possible use of molecular simulations to determine the desired properties of
potential ﬁbrillation inhibitors are offered.
INTRODUCTION
Amyloid ﬁbrillation is the process of native soluble proteins
misfolding into insoluble ﬁbrils comprising cross-b-sheets.
More than 20 amyloidogenic diseases such as Alzheimer’s
disease, Parkinson’s disease, and prion-associated encepha-
lopathies have been found to share ﬁbril formation as the
common symptom (1). The presence of amyloid plaques cor-
relates with disease, but whether ﬁbrils themselves, misfolded
oligomers, or other factors are the causal agents of diseases
remains unclear (2–4). Although the proteins associated with
each disease do not share sequence homology, they exhibit
similar insoluble ﬁlaments and ﬁbrillation responses (5,6).
This suggests that the underlying ﬁbril formation mecha-
nisms may be common (7).
The typical ﬁbril formation process starts with a lag phase
in which the amount of amyloid proteins turned into of ﬁbrils
is not signiﬁcant enough to be detected. Afterwards, a drastic
elongation phase follows and ﬁbril concentration increases
rapidly (8). Eventually, the process reaches equilibrium when
most soluble proteins are converted into ﬁbrils. The length of
lag times and ﬁbril growth rates depend upon factors like the
initial concentration and pH, both of which affect the degree
of supersaturation in solution. The presence of seeded mole-
cules and foreign surfaces can inﬂuence the kinetics of ﬁbril-
lation, because of the ability to catalyze the reactions at these
interfaces (9). Other factors include the ionic strength of the
solution and the intensity of agitation (10). Although experi-
mental data covering these many different conditions have
been reported in the literature, there is a noticeable lack of
quantitative mechanistic models to provide insight into the
process and directions for further research.
Because of the commonly observed sigmoidal-shaped
ﬁbrillation response reported in the literature (10,11), ﬁbril-
lation processes have been modeled as a number of reactions
in series covering the assembly of oligomers, the formation
of nuclei as well as the growth and the breakage of ﬁbrils
(3,12,13). Moreover, the two-stage mechanism of yeast prion
ﬁbrillation, in which ﬁbrils act as enzymes to trigger nu-
cleated conformational conversion by Michaelis-Menten ki-
netics, provides another valuable perspective (14). Empirical
or semi-empirical exponential functions are popular choices
to ﬁt the data since they are computationally simple and match
the observed data well (10,15). While suggestive, some of
these models only depicted the sigmoidal trend without rigor-
ous quantitative arguments; others have not provided details
on how the nuclei form or explained the shortened lag-time
resulting from seeding and an increase in the initial protein
concentration.
The lag-time before ﬁbril growth has been noted in numer-
ous publications and resembles an incubation period (10,11).
Explaining its existence is one of the key scientiﬁc chal-
lenges. The problem was approached by Shoghi-Jadid et al.
(16) with introduction of the Heaviside function to force
the separation of nucleation and ﬁbrillation processes, while
Uversky et al. (17) used an empirical exponential model with
adjustable parameters. We suggest that nucleation theory and
growth models could be valuable in describing the ﬁbrilla-
tion process. Furthermore, the drastic rate increase in the
ﬁbrillar growth phase after the lag phase indicates that co-
operativity or positive feedback mechanisms are involved.
Another critical but missing piece of information is the
relationship between the observable response and the degree
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of ﬁbrillation. Even though histological dyes like thioﬂavin
T (ThT) and Congo Red have been the commonly used as
indicators of the presence of amyloid ﬁbrils, the relationship
between ﬂuorescence intensity and amount of amyloid ﬁbril
remain unclear (18,19). There are also physical property
methods for measuring ﬁbril formation like turbidity, ab-
sorbance, and sedimentation (11,20). Here, we assumed lin-
earity between ThT ﬂuorescence and ﬁbril concentrations
based on Beer-Lambert law as a measure of ﬁbril content,
and use ultraviolet-visible (UV-vis) absorbance at 280 nm as
a quantitative measure of dissolved total protein.
Insulin (51 aa; 6 kDa) was chosen as the model protein for
the measurements in this study because it 1), is a well-studied
ﬁbril-forming protein and has recently been studied in our
laboratory (A. Nayak, A. Sethuraman, T. M. Snyder, C.-C.
Lee, G. J. McRae, and G. Belfort, unpublished; (22)); 2), has
been crystallized in the native state at high resolution; 3), is
known to develop structurally similar cross-b-sheet plaques
to those formed by other amyloids and is deposited in arterial
walls of type II diabetes patients (23); and 4), is available in
large quantities at reasonable price. Native insulin is well
folded and in stable hexamer state associated with Zn21 mol-
ecule under physiological conditions. Yet it can be readily
unfolded to form ﬁbrils in solution by both increasing the
temperature to 65C and by reducing the pH to 1.6. Jime´nez
et al. (28) proposed that the a-helical structure (58%) of
native insulin becomes unfolded to expose the b-sheet region
(6%), which is the major component of the amyloid cross-b
ribbon.
In the next section, we describe the proposed kinetic
model for insulin ﬁbrillation including the parameter esti-
mation procedure. Since experimental protocols and responses
of ﬁbrillation are similar among amyloid proteins, the model-
ing approach presented here is also applicable to the ﬁbril-
lation of other proteins. Afterwards, our model is compared
with an empirical ﬁtting function. A general description of
the Experimental Materials and Methods follows. Then, in
Results and Discussion, the new model is ﬁtted to our insulin
ﬁbrillation data, to ﬁbrillation of Ab-40 and prionlike NM
fragment of Sup-35 (11,24), and to data conducted under
various conditions (i.e., increasing initial insulin concentra-
tion, effect of seeding, stirring effects).
A kinetic model for insulin ﬁbrillation
Three standard analytical steps were chosen to model insulin
ﬁbrillation: formulation of the appropriate kinetic reactions
based on the polymerization and nucleation theories, conver-
sions of the reaction set into a system of differential equa-
tions, and parameter estimation by nonlinear least-square
algorithms to optimize the ﬁt between simulation results and
the experimental measurements.
Initially four species of insulin were considered during
ﬁbrillation: original hexamer, monomer, cluster, and ﬁbril
(20,25). While the original hexamer is composed of six
monomers stabilized by Zn21, an insulin monomer refers to
two chains of polypeptides connected with disulﬁde bonds
(the A- and B-chains comprising 21 and 30 amino acids,
respectively). For systems other than insulin, different mor-
phologies may be involved such as those for b2-microglob-
ulin (26). By incorporating the four insulin species into the
reaction scheme, the proposed kinetic mechanism for this
study consists of three distinct stages: decomposition of
hexamers, nucleation process, and ﬁbrillation stage as sum-
marized in Fig. 1 and Table 1. All the reactions listed are
elementary reactions so the ﬂuxes can be easily expressed as
the products of reactant concentrations and the rate constant.
Regarding notations, Ahex and Ai denote the concentration of
original insulin hexamers and oligomers containing i mon-
omers, respectively. All ﬁbrils are abbreviated as F, regardless
of their length. Even though physical reactions contributing
to larger-size cluster formation and the entanglement be-
tween strands of ﬁbrils have been reported (28,29), the actual
active chemical reaction sites are assumed to be restricted to
the ﬁbril ends (20). Therefore, ﬁbrils of different sizes can be
considered as the same species.
Key reaction species interact with one another and reac-
tions proceed as summarized in Table 1. First, the zinc-
stabilized hexamers are assumed to irreversibly misfold and
dissociate into monomers containing cross b-sheets under
stringent conditions like low pH and high temperature (30).
Since the dissociated form of insulin has been reported to
readily misfold into reactive monomers (28), the misfolding
step is assumed to occur very fast. In this case, the disso-
ciation step is rate-limiting with the rate constant kd. Second,
the mechanism of nucleation is based on the Becker-Do¨ring
nucleation model from the ﬁeld of atmospheric science (31).
Accordingly, the newly formed monomers react with one
another as well as with different size oligomers so as to
become larger clusters. The reactions between larger oligo-
mers are negligible because their early concentrations and
diffusivities are relatively low and small, respectively, as
compared with the monomers. As oligomers grow, their chem-
ical potentials drop, yet the surface tension to form new
phases rises. Hence, there should exist a condition with mini-
mum Gibbs free energy corresponding to the size of a cluster
FIGURE 1 The key species in the proposed three-stage reaction mech-
anism of insulin. The images of the hexamer and ﬁbril were redrawn based
on the literature (27,28).
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(or nuclei), (n–1)-mer (31). Any aggregates larger than the
cluster would convert into ﬁbrils. Once the ﬁbrils are formed,
their ends serve as nuclei and undergo self-catalytic reactions
to become longer ﬁbrils with kfb,i and kfb,i as the forward
and reverse rate constants (32). At this stage, reactions be-
tween ﬁbrils and all sizes of oligomers need to be taken into
account since the reactive nature of ﬁbril ends greatly ac-
celerates the process. Finally, the reactions of i-mer addition
and detachment proceed until the clusters are depleted and
reach equilibrium with ﬁbrils.
After the kinetic schemes are established, the concentra-
tions of various species are expressed as functions of time.
The temporal change of these species can be derived from
material balances and reaction kinetics. The ﬁrst specie to
be considered is the original insulin hexamer whose rate of
change is expressed as the disappearance by dissociation
(Eq. 1):
dAhex
dt
¼ Jd: (1)
The rate of monomer concentration change can be calcu-
lated by taking into account all the reactions involving mono-
mers in Table 1. As a result, the time derivative of A1 equals
the generation rate from the hexamer dissociation reaction
minus the consumption rate due to all nucleation reactions,
and the ﬁrst elongation reaction (Eq. 2). The constants before
Jd and Jnu,1 are the stoichiometric coefﬁcients:
dA1
dt
¼ 6Jd  2Jnu;1  +
n1
i¼2
Jnu;i  Jfb;1: (2)
Then the concentration change of i-mer clusters is equal to
its formation rate from the (i–1)th nucleation reaction minus
the consumption rate due to the ith nucleation reaction and
the ith elongation reaction (Eq. 3):
dAi
dt
¼ Jnu;ði1Þ  Jnu;i  Jfb;i for i ¼ 2; 3; . . . ; n 1: (3)
The addition of monomer to the largest possible cluster
(An1) results in ﬁbril formation as the last reaction at the
nucleation stage suggests. Hence, the time derivative of ﬁbril
concentration is equal to the ﬁbril generation rate subtracted
by its consumption rate, i.e., the net ﬂux of last nucleation
reaction (Eq. 4). Note that the ﬁbril elongation process ac-
tually does not affect ﬁbril concentration since no additional
ﬁbrils are formed or consumed at that stage:
dF
dt
¼ knu;ðn1ÞA1An1  knu;ðn1ÞF: (4)
The initial concentration of insulin hexamers is equal to
the amount of insulin added initially and is the main driving
force for the downstream reactions (i.e., Ahex ¼ Ahex0). The
concentrations of the other species are assumed to be zero at
the start (i.e., Ai ¼ 0, F ¼ 0). Equations 1–4 contain totally
n11 variables with equal number of corresponding differ-
ential equations and initial conditions. Thus, the system of dif-
ferential equations is properly deﬁned and ready to be solved
once the values of all parameters are speciﬁed.
Even though the model contains quite a few parameters,
some of them are physically related to one another; others
can be found from the literature. Three assumptions were made
to reduce the total number of parameters:
1. The value of n, the critical number of monomers needed
to form a nucleus, has been reported as six (16), so ini-
tially we have set n equal to six. However, we also dis-
cuss the sensitivity of this parameter on the model ﬁt in
the section In Vitro Fibrillation Kinetics. The dissociation
rate constant of insulin kd can be estimated from the insu-
lin dissociation time of ;1 h (33). Assuming that 1 h is
approximately the time to reach 95% conversion of ex-
ponential decay, kd is ;3 h
1.
2. Since agitation has been found to drastically shorten the
delay time (9), the reaction rates of forward nucleation and
ﬁbrillation (knu,i and kfb,i) are assumed to be diffusion-
limited (20). Apparent rate constants of diffusion-con-
trolled reactions take the form of Eq. 5 (34), in which N˜ is
Avogadro’s number, dAF is the mean free path of the com-
plex molecule, and DA1DF is the sum of diffusivities of
the reactants. The values of diffusivities are proportional
to the inverse of the characteristic length RAi, following
the Stokes-Einstein equation as in Eq. 6 (35). The volume
of i-mer is equal to i times the volume of the monomer
(V1) and is also related to its own characteristic radius
(RAi) through volumetric formula. Thus, the diffusivity is
roughly proportional to the inverted cubic root of i,
which equals the size of the cluster.
TABLE 1 The proposed three-stage model including reaction
ﬂuxes and rate constants
Description of
processes Reaction schemes Reaction ﬂuxes
Hexamer
decomposition
Ahex !kd 6A1 Jd ¼ kdAhex
Nucleation
stage
A11A1 !knu;1 
knu;1
A2 Jnu,i ¼ knu,iA1Ai – knu,1Ai11
A11A2 !knu;2 
knu;2
A3 . . . . . .
A11An2 !
knu;ðn2Þ
 
knu;ðn2Þ
An1
A11An1 !
knu;ðn1Þ
 
knu;ðn1Þ
F
Elongation
stage
F1A1 !kfb;1 
kfb;1
F Jfb,i ¼ kfb,iAiF – Ffb,iF
F1A2 !kfb;2 
kfb;2
F
F1An1 !
kfb;ðn1Þ
 
kfb;ðn1Þ
F
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kD ¼ N˜4pðDA1DFÞdAF; (5)
DAi }
1
RAi
¼ 1ﬃﬃﬃﬃﬃﬃﬃﬃﬃ
3
4p
iV13
p } 1ﬃ
i3
p : (6)
In Eqs. 5 and 6, nucleation and ﬁbrillation forward rate
constants regarding different sizes of oligomer can be ap-
proximated by Eqs. 7 and 8. Because the sizes of oligomers
are comparable and thus their diffusivities are similar, both
diffusivities need to be taken into account in the nucleation
process. On the other hand, in the case of ﬁbrillation, since
the sizes of ﬁbrils are much larger than those of oligomers,DF
is negligible compared toDAi, and, therefore, the diffusivity of
the oligomer is the dominant term:
knu;i ¼ 1
2
knu;1ð11 1ﬃ
i3
p Þ} 4pðDAi 1DA1Þ; (7)
kfb;i  kfb;1 1ﬃ
i3
p } 4pDAi : (8)
3. The values of knu,i and kfb,i are assumed to be in-
dependent of size i, and are abbreviated as knu and kfb,
respectively. Serio et al. (20) showed that sonicated seeding
provided a larger amount of ﬁbril ends as reactive sites and
demonstrated higher reaction rate. This suggested that
under normal conditions, the detachment of oligomers often
occurs at the terminal rather than in the internal segment.
Hence, for this study, the number of monomers within a
chain or oligomer does not affect the reverse rate
signiﬁcantly.
Parameter estimation and model comparison
The predictions of Eqs. 1–4 were compared with the ex-
perimental data (i.e., values of the species concentrations) to
estimate the rate constants. There were four kinds of ob-
servable data considered: ThT ﬂuorescence, UV-Vis absor-
bance at 600 nm (A600), turbidity, and dissolved insulin
concentrations (absorbance at 280 nm, A280). The ﬁrst three
measures were assumed to be roughly proportional to the
insulin ﬁbril concentrations by Beer-Lambert law (19), and
denoted as Y ¼ b 3 F. The last measure was simulated by
counting total number of i-mers in the unit of monomer
concentration, which could be expressed as Y ¼ Si Ai 3 i.
Nonlinear least-square regression was adopted to minimize
the sum of squared errors between experimental data and
those predicted by the model; parameter estimation proce-
dures were carried out in MatLab (The MathWorks, Natick,
MA). Detailed algorithms are given in the Supplementary
Material (37).
In the past, an empirical function like Eq. 9 has been used
in the literature to ﬁt the ﬂuorescent ThT data with time data
(10,17). Independent of the amyloid protein type, Eq. 9 ﬁts
the ﬁbrillation data reasonably well. This again suggests that
the ﬁbril formation process is similar for these different pro-
teins. It is a specialized form of the logistic function, which
has been frequently used in the ﬁeld of population biology
(38). The parameters from this model include the apparent
rate constant for the growth of ﬁbril (kapp), and the lag time,
which are equal to 1/t and t0–2t, respectively:
Y ¼ yi1 yf
11 eðtt0Þ=t
: (9)
In the Supplementary Material, it is shown how to relate
the parameters in this empirical model to the kinetic rate
constants in Eqs. 1–4 under simplifying assumptions. That
is, when the critical size of a nucleus (n) is equal to 2, there is
an analytical solution for the only two species, A1 and F. By
mass balance, A1 ¼ A0–F  N (where A0 is initial concen-
tration and N is the average ﬁbril size).
dF
dt
¼ knu;1A211 kfb;1FA1  kfbF} ðF r1ÞðF r2Þ; (10)
F ¼ r11 r2  r1
11 eðtt0Þ=t
; (11)
1
t
¼ ðNkfb;1  N2knu;1Þðr2  r1Þ and t0 ¼ tlnðr2=r1Þ:
(12)
The time derivative for the ﬁbril concentration can be
reduced to a quadratic differential equation (Eq. 10). The
two roots of the equation, r1 and r2, are obtained from the
quadratic formula and correspond to the steady-state ﬁbril
concentrations. Equation 11 is the solution of Eq. 10 by
integration. It expresses the temporal evolution of the ﬁbril
concentration, and has the equivalent functional form of Eq.
9. The observable delay lag and growth rates can be related
to the kinetic constants by Eq. 12.
EXPERIMENTAL
Materials
All chemicals were obtained from Sigma Chemical (St. Louis, MO).
Recombinant human insulin was generously donated by Novo Nordisk A/B
(Bagsvaerd, Denmark). All insulin solutions used for the in vitro ﬁbril
formation experiments were freshly prepared before each experiment in
0.025 M HCl, 0.1 M NaCl and adjusted to pH 1.6. Each sample for the
kinetic experiments contained 1 ml of 2 mg/ml insulin in glass vials and was
incubated at 65C. At appropriate time intervals, the sample was removed
from the incubator for analysis.
Methods
UV-Vis absorbance assay
In vitro insulin ﬁbril formation has been shown to result in the formation of
insoluble aggregates, which are b-sheet rich structures (10). The UV-visible
absorbance assay at 600 nm wavelength (A600) has been extensively used to
quantify insoluble aggregates like inclusion bodies and cell debris from cell
culture and is also used frequently in molecular biology studies. Here, we
quantify the amount of insoluble protein (ﬁbrils) and soluble protein by
measuring the absorbance of the solutions at 600 nm and 280 nm, respec-
tively. The absorbance was measured on a Hitachi U 2000 Double-Beam
UV/VIS spectrophotometer (Hitachi Instruments, Danbury, CT). Spin-x
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centrifuge tube ﬁlters (Dow Corning, Corning, NY) of 2 ml total volume
with 0.22-mm pore-size cellulose acetate membranes were used for
separating the ﬁbrils from the soluble protein. Centrifugation was conducted
at 10,000 g for 10 min to separate the ﬁbrils from the supernatant. Then, the
protein concentration in the supernatant was measured at 280 nm using a
calibration curve.
RESULTS AND DISCUSSION
The model is ﬁrst ﬁtted to the data from our laboratory for the
ﬁbrillation of human recombinant insulin. We then tested the
model with the experimental dataset from the literature,
including ﬁbrillation data of other proteins, at different initial
concentrations, with and without seeding, and at different
stirring rates. In addition, the kinetic rate constants for those
experiments were estimated and compared.
In vitro ﬁbrillation kinetics
Two experimental assays were followed during the in vitro
insulin ﬁbrillation process. The UV-visible absorbance assay
at 600 nm wavelength (A600) was used to follow the for-
mation of ﬁbrils and A280 was used to track total protein
after removing the ﬁbrils with microﬁltration. As seen in Fig.
2 A, the two sets of data closely followed each other with a
sigmoidal and inverse sigmoidal curve. This result demon-
strates that mass from the dissolved protein was used to form
the ﬁbrils and that the mass balance closed fairly well. To test
the validity of the ﬁrst assumption regarding n, the critical
size of nucleus, the data in Fig. 2 A was ﬁt with different
values of n (results not shown). The R2 value was the highest
for n equal to six and dropped below 0.9 for n smaller than
four or larger than nine. While nucleus sizes may take dif-
ferent values, statistically six was the least-squares estimator
that minimized the sum of squared errors. Thus, the assump-
tion of n ;6 is reasonable for this study. Further experi-
ments that measure ﬁbril size distribution with time are clearly
needed.
Since two independent measurements, A600, and A280,
were used to follow the gain in ﬁbrils and loss in protein with
time, respectively, the model was ﬁrst ﬁt to each separate set
of data and then to both sets of data simultaneously to obtain
the values of the rate constants listed in Table 2 together
with the goodness-of-ﬁt estimates. In addition, the deﬁnition
of each symbol is summarized in Table 3. First, the values of
knu,1 are approximately eight orders-of-magnitude smaller
than those of kfb,1, which conﬁrms the widely held view that
the nucleation rate was rate-limiting and that ﬁbrillation was
extremely fast. For ﬁts of both sets simultaneously (combined),
the rate constants were knu,1 ¼ 3.74 3 102 (h1 mM1),
knu ¼ 1.01 3 103 (h1), kfb,1 ¼ 2.75 3 106 (h1 mM1),
and kfb ¼ 1.84 3 103 (h1). This set of rate constants was
then chosen for the sensitivity analysis reported in the Sup-
plementary Material to evaluate the impact of each parameter.
Since several folds of change in knu barely altered the
FIGURE 2 Insulin ﬁbrillation in solution was monitored
by UV-Vis spectroscopy. (A) The experimental data and
simulated responses for two different assays: A600 (open
symbols) for suspended ﬁbrils and A280 (solid symbols) for
total dissolved protein, respectively. Each symbol is for a
single experimental run. The solid lines are the overall
optimal nonlinear least-square ﬁt while the thin dotted
lines represent the 95% conﬁdence interval. (B) Simulated
concentration proﬁles versus time for monomer, original
hexamer, dimer, and ﬁbril. (C) The corresponding proﬁles
for 3-mer, 4-mer, and 5-mer.
3452 Lee et al.
Biophysical Journal 92(10) 3448–3458
ﬁbrillation proﬁle, knu was not further considered for the
parameter optimization (Supplementary Material Fig. S1).
Thermodynamically, the rate constants are related to the
Gibbs free energy of transition from the monomer to the
nuclei, (n–1)-mer. By summing up all the reactions except
the last one in the nucleation process in Table 1, we obtain
Eq. 13 below. The standard Gibbs free energy can be cal-
culated from equilibrium constants with Eq. 14 (31), where
DG denotes the free energy difference between monomers
and (n–1)-mer clusters. The higher the ratio of the forward to
the reverse rate constant, the more likely will the monomers
convert to nuclei. Our calculated value of DG is 42.66 12.2
kJ/mol, which is of the same order of magnitude as that
reported for amyloid ﬁbers, 33.4 kJ/mol (39). Further, since
the values of knu,i are larger than knu, the free energy should
be negative and the nucleation process is spontaneous.
ðn 1ÞA1 !  An1; (13)
DG
+ ¼ RT lnKc ¼ RT ln
Yn1
i¼1
knu;i
knu
: (14)
The model is also able to track various insulin species such
as initial hexamers, monomers, dimers, other oligomers, and
ﬁbrils. It can be seen from Fig. 2, B and C, that 1), all the
initial zinc stabilized hexamer had disappeared by ;2 h; 2),
monomer reached a maximum at;1 h and disappeared by 6
h; 3), very little dimer was present; 4), signiﬁcant ﬁbril
formation occurred at;3.5 h and saturated at;5.5 h; and 5),
formation and growth of trimers was faster than 4- and
5-mers and all three saturated at ;5.5 h. The experiment
starts off with the rapid breaking down of original insulin
hexamers, which gives rise to a drastic increase of monomer
concentration. During the second stage (1–4 h), a quasi-
steady state of cluster distribution appears and the oligomer
concentrations rise slowly at the expense of disappearingmono-
mers (40). After the wave front reaches a certain critical
condition, sufﬁcient ﬁbril ends are formed to serve as active
sites for further elongation. The autocatalytic nature of the
newly formed ﬁbrils ignites the creation of clusters rapidly
through a positive feedback loop until the monomers are
depleted and oligomers reach their steady-state concentra-
tions. These simulation results clearly describe the sigmoidal
curves shown in Fig. 2 A for the formation and disappearance
of ﬁbrils and proteins, respectively.
Since sigmoidal behavior for most amyloidogenic proteins
has been observed, this similarity in the response of many
proteins suggests a common mechanism (6,7,14). We decided
to test our model with ﬁbril formation data from the literature
for several other such proteins. First, Sup-35 is a yeast trans-
lation termination factor known to assemble in a prionlike
form with its N and M segments governing prion formation
(24). Likewise, Ab-40 is a protein fragment that aggregates
into amyloid plaques and has been found in the brains of
Alzheimer’s disease patients (11). However, for proteins other
than insulin we needed to replace the hexamer dissociation
step with a fast misfolding reaction. Shown in Fig. 3 are the
ﬁbrillation data for a NM amyloid fragment of Sup-35 at
2.5 mM and the Ab-40 segment at 80 mM as well as the best
ﬁts (solid lines) (11,24). The coefﬁcients of determination
and kinetic rate parameters are listed in Table 2. The large R2
values indicate the model ﬁts the data well. For both NM and
Ab-40, the values of the nucleation rates (knu,1) are several
orders-of-magnitude faster than those for insulin. This result
is consistent with reports in the literature that indicate the
ease of forming ﬁbrils with NM and Ab-40 (11,24). This
demonstrates the ﬂexibility of the model and suggests that
TABLE 2 Rate constants obtained by ﬁtting the kinetic model to various experimental conditions (with mean 6 1 SD)
Factors Figure no. Experimental notes and references knu,1(h
1 mM1) kfb,1(h
1 mM1) kfb(h
1) R2
Solution Fig. 2 A Insulin, absorbance @600 nm 3.54 6 2.12 3 102 2.73 6 0.66 3 106 1.93 6 1.87 3 103 0.94
Insulin, concentrations 4.72 6 1.60 3 102 3.85 6 3.59 3 106 1.30 6 0.66 3 103 0.98
Insulin, combined 3.74 6 1.13 3 102 2.75 6 0.48 3 106 1.84 6 0.42 3 103 0.95
Fig. 3 Prion (24) 7.10 6 6.73 3 102 1.51 6 1.22 3 104 1.26 6 2.04 3 101 0.99
Ab1–40 (11) 1.38 6 0.53 3 100 1.37 6 1.22 3 104 3.02 6 2.64 3 102 0.99
Initial concentration Fig. 4 A Insulin, all concentrations (10) 3.20 6 0.42 3 101 4.50 6 0.50 3 105 4.00 6 0.88 3 101 0.92
Seeding Fig. 5 Insulin, 0 and 10% (43) 7.90 6 1.40 3 102 1.52 6 4.17 3 106 1.99 6 1.16 3 101 0.87
Stirring Fig. 6 Insulin, 80 rpm (9) 1.43 6 0.75 3 101 4.20 6 1.15 3 106 7.14 6 2.47 3 100 0.99
Insulin, 160 rpm (9) 2.68 6 4.12 3 101 1.27 6 5.27 3 107 5.19 6 3.60 3 101 0.99
FIGURE 3 The ﬁbrillation responses for 2.5 mM NM amyloid fragment
of Sup-35 from yeast monitored by ThT ﬂuorescence (s). Data source:
Krishnan et al. (24). The ﬁbrillation responses for 80 mMAb1–40 measured
by turbidity assay (h). Data source: Evans et al. (11). The solid lines are the
optimal nonlinear least-square ﬁt.
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the mechanism among amyloid proteins may be similar.
More importantly, this model can potentially serve as the
template for comparing and unifying data sets across
different protein experiments carried out under various oper-
ational conditions such as changing initial concentrations,
seeding, and stirring. These effects are addressed next.
Initial concentration effects
Data from Fink’s group (10) showing the effect of varying
initial concentration (0.2–20 mg/mL) of human recombinant
insulin on the ﬁbrillation are reproduced in Fig. 4 A. Clearly,
the higher the initial concentration of insulin, the shorter the
lag-time and the steeper the growth curve. However, as can
be seen from the ﬁgure, the ThT intensity asymptotes for
long times are not proportional to the initial amount of
protein in the feed. This result coincides with other results in
TABLE 3 The summary of nomenclature
Symbols Units Deﬁnitions
A0 mM Initial insulin concentration.
A1 mM Insulin monomer or insulin monomer concentration.
Ahex mM Original insulin hexamer or its concentration.
Ai mM Insulin cluster consisting of i monomers or its
concentration.
b mM1 Proportional constant relating ﬁbril concentration to
experimental signal.
dAF m The mean free path between monomer and ﬁbril.
DAi m
2 s1 Diffusivity of oligomer Ai.
DF m
2 s1 Diffusivity of ﬁbril.
DG Kcal/mol Gibbs free energy of the reaction of monomers
becoming (n–1)-mers.
f — Our ﬁbrillation model expressed as a function.
F mM Fibrils or ﬁbril concentration.
i Number Our ﬁbrillation model expressed as a function.
Jhex h
1 mM The reaction ﬂux of original insulin decomposition.
Jnu,i h
1 mM The ﬂux of ith nucleation reaction.
Jfb,i h
1 mM The ﬂux of ith ﬁbrillation reaction.
kapp h
1 The apparent growth rate of ﬁbril, which is equal
to 1/t.
Kc mM
(n2) Equilibrium constant between monomers
and (n1)-mers.
khex h
1 Reaction rate constant of original insulin
decomposition.
kfb h
1 General reverse rate constant of ﬁbrillation reaction.
kfb,1 h
1 mM1 Forward rate constant of the ﬁrst ﬁbrillation
reaction.
kfb,i h
1 mM1 Forward rate constant of ith ﬁbrillation reaction.
kfb,1 h
1 Reverse rate constant of ith ﬁbrillation reaction.
knu,1 h
1 mM1 Forward rate constant of the ﬁrst nucleation
reaction.
knu h
1 General reverse rate constant of nucleation reaction.
knu,i h
1 mM1 Forward rate constant of ith nucleation reaction.
knu,i h
1 Reverse rate constant of ith nucleation reaction.
mi, mf h
1 The slope of initial and ﬁnal ﬁbrillation response
curve, respectively.
n Number Critical number of monomers in a nucleus.
nexp Number The number of experimental data points.
N Number The average size of ﬁbrils in terms of number
of monomer.
N mol1 Avogadro constant.
F(u) — The objective function to be optimized with
respect to u.
R J/mol K Ideal gas constant, 8.314.
R2 — Coefﬁcient of determination.
RAi m Characteristic length of oligomer Ai.
r1, r2 mM The ﬁrst and second roots of the ﬁbril
quadratic equation.
t0 h The time to 50% of maximal signal or the time of
inﬂection point.
ti h The time of i
th experimental data point.
tn,a/2 — Student’s t-distribution with degree of freedom n,
signiﬁcance level a.
t h The time constant of ﬁbril growth; it is equal
to 1/kapp.
u — The vector of parameters to be estimated.
V1 m
3 The mean volume of a monomer.
X — Linearized design matrix (Jacobian matrix).
Y — UV-vis absorbance of ThT ﬂuorescence intensity.
FIGURE 4 Initial concentration effects on insulin ﬁbrillation were moni-
tored by ThT ﬂuorescence. (A) The experimental measurements and simula-
tions of ﬁbrillation responses starting at seven initial insulin concentrations:
20 mg/ml (d), 10 mg/ml (s), 5.0 mg/ml (:), 2.0 mg/ml (n), 1.0 mg/ml (n),
0.5 mg/ml (h), and 0.2 mg/ml (¤). The solid lines are the optimal nonlinear
least-square ﬁt. Data source: Nielsen et al. (10). (B) The estimated activity
coefﬁcients (d) and equilibrated ThT:ﬁbril complex concentrations (n) as
functions of initial insulin concentrations. The lines are used to connect the
calculated points and do not represent a ﬁt.
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our group (unpublished). Thus, ThT ﬂuorescence does not
grow linearly with respect to the amount of ﬁbers present. By
applying a single set of kinetic rate constants for seven dif-
ferent initial concentrations, our initial simulations did show
consistent trends. However, at ﬁrst the simulated asymptote
of each individual concentration could not match the experi-
mental results.
To quantify the concentration results better, nonlinear
effects from at least two possible sources should be con-
sidered: the nonideal behavior of proteins at high concen-
trations, and a possible artifact from the ﬂuorescence ThT
assay. The activity coefﬁcients of proteins at high concen-
trations are typically not constants and should be considered
in the model (41). Second, as mentioned above, nonlinearity
with the ThT signal exists perhaps because ThT measure-
ments depend on the ThT:ﬁbril formation, which involves
stoichiometric binding of both compounds (18). This non-
linear relationship is unknown so the proportionality con-
stants based on each curve was estimated. The ﬁrst step was
to estimate the activity of insulin at each concentration based
on the experimental data given a set of kinetic rate constants.
Afterwards, the activity coefﬁcients were computed by divid-
ing the activity values by the original concentrations. Finally,
the concentration of ThT:ﬁbril complex was the product of
proportional constant and asymptotic ﬁbril concentration.
The values of the activity coefﬁcient and ThT:ﬁbril complex
concentration are summarized in Fig. 4 B. As expected from
estimates using the equation of state, it can be seen from Fig.
4 B that the calculated activity coefﬁcients decreased with an
increase in the initial insulin concentration. On the other
hand, since the amount of ThT added in each run was ﬁxed
regardless of the initial amount of insulin added, it became
the limiting agent at high insulin concentration. Thus,
ThT:ﬁbril complex concentration did not rise linearly with
increasing initial insulin concentration, but appeared to reach
an asymptote.
After the adjustment regarding the nonlinearity, the simu-
lated results by our model match the experimental data better.
Yet additional experiments that measure the actual protein
quantities by osmotic pressure, for example, and determine
the multivariate relationship between ThT concentration, am-
yloid ﬁbrils, and ﬂuorescence signal would be useful in test-
ing our hypothesis.
Effects of seeding
The addition of ﬁbril seeds to a solution that is in the process
of forming ﬁbrils shortens the lag time. This effect has been
termed a ‘‘nucleation-dependent’’ phenomenon byWood et al.
(42). They explained that the added seeds act as catalytic
sites that induce conformational changes in the protein
(a-synuclein) and accelerate the reaction rates; also Scheibel
et al. (14) have termed this nucleated conformational con-
version. In Fig. 5 both the effect of adding seeds to the initial
insulin solution (2 mg/ml) and our simulation results are
shown (43). For the simulations, a single set of rate constant
values was used for both curves because seeding only in-
creases the likelihood of collision but not the probability of
the corresponding reaction actually taking place. Since only
the weight of the added ﬁbril seeds was reported, the number
of reactive ends was not known (nor details about the length
distribution of ﬁbrils). Thus, the estimated initial ﬁbril con-
centration was obtained by minimizing the total sum of
squared errors from both data sets with and without seeding.
The best estimate for the initial concentration of ﬁbril was
2.53 3 107 mM for a 10 wt % addition of seeds. This low
value supports the hypothesis that ﬁbril ends were the re-
active sites although ﬁbrils were composed of a large number
of monomers (20). As can be seen from the ﬁt of the model to
the data in Fig. 5, the model does not capture the effect of the
shortened lag-time very accurately. A possible reason was
that there exists size distribution of the added seeds and
clusters. Unfortunately, without knowledge of this distribu-
tion, an estimate of the total added number of ﬁbril ends was
made. This likely oversimpliﬁed the seeding processes.
The explanation of the seeding effect from this analysis
is based on the fact that the rate constants for ﬁbril growth
were orders-of-magnitude larger than those for the nuclea-
tion process. Hence ﬁbril growth could not take place unless
sufﬁcient amounts of nuclei were present. Therefore, the ad-
dition of seeded ﬁbrils allows the system to bypass the slow
nucleation phase and reach the growth phase much faster and
earlier.
Stirring effects
It has been reported that stirring or shaking can shorten the
lag phase and speed up the ﬁbrillation process. One proposed
reason for these effects was that agitation would increase the
air-water interface and the presence of additional hydropho-
bic interfaces (air) would accelerate nucleation (9). Other
FIGURE 5 The measured and simulated ﬁbrillation responses without
seeding (s) and with 10 wt % seeding (h) were monitored by ThT ﬂuo-
rescence. The solid lines are the simulated responses with initial insulin con-
centration equal to 2 mg/ml. Data source: Hong and Fink (43).
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possible explanations include that additional mixing accel-
erates polymerization by breaking up large complexes and
increasing the collision of reactive complexes with each other
and with ﬁber ends (20). Fig. 6 contains the transient responses
of measured as well as simulated dissolved insulin concen-
trations under different rotational speeds for an initial con-
centration of 0.6 mg/ml (9). Both demonstrate that higher
rotational speed results into faster ﬁbrillation and shorter lag
times. From Table 2, the rate constants increase for nu-
cleation and for ﬁbril formation with increased mixing. That
is, the values of knu,1 and kfb,1 roughly doubled and tripled,
which suggest an increase in the mass transfer coefﬁcients
caused by a higher collision rate between monomers and
oligomers as well as betweenmonomers and ﬁbrils. The nearly
four fold increase in kfb indicates that the ﬁbers were losing
oligomers from the end of the ﬁbrils to create new nuclei.
A simple ﬁlm theory can be adopted to predict the ap-
parent rate constants under the inﬂuence of both transport
and reaction (44). According to this theory, transport and
reaction resistances are in parallel and additive. Hence, being
limited by diffusion at ﬁrst, the rate of stationary process
may increase and become reaction-controlled under stirring.
The faster rotation initially results in larger apparent rate
constants but the process may eventually become reaction-
controlled. Beyond that point, even more vigorous stirring
and hence convection would not speed up the reaction any
longer. Measuring ﬁbrillation responses under different rota-
tional speed can help estimating the amount of kinetic energy
needed to overcome the diffusion barrier.
CONCLUSIONS AND FURTHER DEVELOPMENT
A three-stage model of ﬁbrillation developed here was able
to simulate the experimental data measured by us and by
others. Hence, it provides a physical rational for the generic
sigmoidal (formation of ﬁbrils) and inverse sigmoidal (loss
of protein) ﬁbrillation responses. In addition to the autocat-
alytic nature of ﬁbril growth, the large difference between
nucleation and growth rate constants lead to ultrafast growth
of ﬁbrils after the lag period. Estimated from the ratio of the
forward and backward nucleation rate constants, the Gibbs
free energy change (DG) of spontaneous reaction involving
insulin monomers converted into nuclei was as large as 42.6
kJ/mol. In comparison with the logistic equation used by
Nielsen et al. (10) and others, the computational model pre-
sented here can be simpliﬁed into the same functional form
to ﬁt ﬁbrillation responses. The physically meaningful rate
constants in our model correspond to experimentally observ-
able variables. Previous mechanistic models have provided
insight, such as the enzymatic nature of the ﬁbril ends (14),
the critical size of nucleus (16), and detailed equations from
population balances (25). Yet most of these models do not
explicitly predict the delay time, nor do they follow the
sigmoidal behavior observed during experiments. For incor-
porating sets of nucleation and elongation reactions, the pres-
ent model and the one proposed by Flyvbjerg et al. (13) both
demonstrate better goodness-of-ﬁt. Yet of these two models
the detailed reactions schemes and predicted asymptotic olig-
omer concentration are different. It will take further work to
differentiate these two models to determine the applicability
of each one.
Based upon the proﬁles of insulin ﬁbrillation, the values of
the same rate constant (knu,1, kfb,1 or kfb) estimated under
different conditions of initial insulin concentration, seeding,
or mixing effects were relatively close. On the contrary, prion
and Ab1–40 demonstrate nucleation rates several orders
faster than those for insulin, because both proteins are known
to form ﬁbrils under mild conditions (physiological pH and
room or physiological temperature). For the initial insulin
concentration effects, the simulated responses starting at dif-
ferent initial concentrations show a consistent trend with the
experiments. The seeding effects of shorter lag time and faster
growth rate were reﬂected in the predicted results by in-
troducing a hypothetical amount of additional initial ﬁbrils.
The stirring raised the nucleation and elongation rates, which
could be due to higher collision rates and more rapid dis-
sociation of oligomers possibly from the ends of ﬁbrils.
Consequently higher reaction rates result in the shorter lag
time and the steeper concentration proﬁle.
Based on the work reported here, the following experi-
ments are suggested to help further conﬁrm a physical basis
of the model and possibly indicate the molecular conforma-
tional properties that would be needed for inhibitors to bind
to the nucleus or other oligomers so as to reduce their toxic
affects. First, it is critically important to quantify the rela-
tionship between the output variables with the state variables
of interest; i.e., match the spectroscopic measurements with
the actual concentrations of ﬁbrils. Second, one needs to track
the temporal evolution of the oligomers (dimers, trimers. . .
nucleus) and ﬁbrils (i.e., ﬁbril lengths and their temporal
distribution) possibly by AFM to verify the critical nucleus
FIGURE 6 The dissolved insulin concentrations measured by UV absor-
bance starting from 0.6 mg/mL under different speeds of stirring: 80 revo-
lutions per minute (rpm) (d), and 160 rpm (n). The solid lines are the
optimal nonlinear least-square ﬁt. Data source: Slusky et al. (9).
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size. Larger-size clusters could be followed using dynamic
light scattering and isolated using a fractionation procedure
together with a toxicity assay to determine actual pathogenic
species (2,12,29,45). Third and fourth, with respect to seed-
ing and agitation effects, a series of carefully designed ex-
periments are needed (20). For example, the number and size
distribution of seeded ﬁbrils should be known and varied
before seeding so as to conﬁrm the importance of the amino
acids at the end of the ﬁbrils or the total number of amino
acids within the ﬁbrils as reactive sites. In all the mixing or
agitation experiments reported to date in the literature, the
fundamental ﬂuid mechanical properties (shear rate and
distribution, vorticity, etc.) of the mixing conditions have not
been reported. Clearly, what is needed is a well-controlled
mixing experiment in which the sigmoidal ﬁbrillation run is
conducted under different and well-designed ﬂuid mechan-
ical conditions. Fifth, it could be very important to vary the
temperature, pH, and ionic strength during ﬁbrillation. One
could then estimate the activation energy and activity co-
efﬁcients for formation of oligomers and ﬁbrils. Sixth, based
on molecular structures of several amyloid peptides that have
been previously simulated (39,46), the aggregation rate
constants among oligomers could be estimated. In brief, our
model extracts rate constants from transient experiments and
bridges the gap between experiments and molecular simu-
lation. This methodology can be used to evaluate the po-
tential ﬁbrillation inhibitors or enhancers by the decrease or
increase in reaction rates they introduce (47).
In summary, amyloid proteins undergo three stages: mis-
folding, nucleation, and elongation, before turning into ﬁbril
aggregates. Validated by many experimental results, this mech-
anistic model is applicable for various types of proteins, and
for ﬁbrillation under different environmental conditions. Fur-
ther experiments tracking oligomer concentrations and theo-
retical analysis of molecular simulations are promising for
determining pathological species and the desired properties
of ﬁbrillation inhibitors.
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